SCHEMBL15568745

SCHEMBL15568745

Cc1c(C(=O)OC(C)(C)C)cc(Br)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
SRD5A1 P18405 1/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA6 Q16445 1/20 0.34
AR P10275 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
EGFR P00533 1/20 0.32
ATM Q13315 1/20 0.32
MAPT P10636 3/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15567724 0.79 GPR35 (0.39) KMT2AMEN1L3MBTL1MAPTALDH1A1
SCHEMBL28984043 0.78 TSHR (0.47) KMT2AMEN1L3MBTL1MAPTALDH1A1
SCHEMBL16418885 0.75 MEN1 (0.32) KMT2AMEN1L3MBTL1ARCNR1
SCHEMBL13171452 0.72 CA12 (0.39) KMT2AMEN1GABRA1GABRG2GABRB3
SCHEMBL828580 0.71 EGFR (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6350428 0.70 CYP2C9 (0.41) KMT2AMEN1GABRA1GABRG2GABRB3
SCHEMBL15567634 0.69 KDM4E (0.39) KMT2AMEN1CNR1CNR2EGFR
SCHEMBL31455587 0.69 LMNA (0.38) KMT2AMEN1GABRA1GABRG2GABRB3
SCHEMBL20140708 0.68 LCK (0.38) AREGFRMAPTCYP2C9CYP2C19
SCHEMBL31073370 0.68 GRM6 (0.35) KMT2AMEN1ARCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 KMT2A 2639/4885SRD5A1 2476/4885MEN1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.